These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 11452249)

  • 1. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
    J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
    Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
    Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?
    Lanes R; Jakubowicz S
    J Pediatr; 2002 Nov; 141(5):606-10. PubMed ID: 12410186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
    Garcia JM; Polvino WJ
    Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.
    Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S
    J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.
    Prahalada S; Block G; Handt L; DeBurlet G; Cahill M; Hoe CM; van Zwieten MJ
    Horm Metab Res; 1999; 31(2-3):133-7. PubMed ID: 10226793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant.
    Hokken-Koelega AC; Stijnen T; de Jong RC; Donckerwolcke RA; Groothoff JW; Wolff ED; Blum WF; de Muinck Keizer-Schrama SM; Drop SL
    Kidney Int Suppl; 1996 Jan; 53():S128-34. PubMed ID: 8771007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
    Blazejewski S; Georges A; Forest K; Corcuff JB; Abouelfath A; Girodet PO; Kamagate M; Jacquet A; Pillet O; Bordenave L; Moore N
    Fundam Clin Pharmacol; 2009 Jun; 23(3):339-44. PubMed ID: 19527301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.
    Zdravkovic M; Christiansen T; Eliot L; Agersoe H; Thomsen MS; Falch JF; Søgaard B; Ynddal L; Ilondo MM
    Growth Horm IGF Res; 2001 Feb; 11(1):41-8. PubMed ID: 11437473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific alterations in insulin-like growth factor-I concentrations in response to 3,3',5-triiodo-L-thyronine supplementation in the growth hormone receptor-deficient sex-linked dwarf chicken.
    Vasilatos-Younken R; Dunnington EA; Siegel PB; McMurtry JP
    Gen Comp Endocrinol; 1997 Jan; 105(1):31-9. PubMed ID: 9000465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism.
    Díez JJ; Grande C; Méndez J; González-Gancedo P; Iglesias P
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):27-34. PubMed ID: 16817815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.